drugset / Trial / NCT02432365
Study of Weekly Paclitaxel and Cisplatin in FIGO IB2 and IIA2 Cervical Cancer Followed by Radical Hysterectomy
Phase 2
Unknown
64 enrolled
Chang Gung Memorial Hospital
Asian Gynecologic Oncology Group · collabTaiwanese Gynecologic Oncology Group · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose was to establish a quick (7-day) cycle schedule of paclitaxel (60 mg/m2) combining with cisplatin (40 mg/m2) NAC regimen could be tolerated without interfering the following surgical treatment and a favorable overall survival rate for stages IB2 and IIA2 cervical squamous cell carcinoma (SCC).
Timeline
- Start
- 2015-02
- Primary completion
- 2023-12
- Completion
- 2023-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cisplatin | Other / unclassified | 40 mg/m2 | — |
| Subject | Paclitaxel | Small molecule | 60 mg/m2 | — |